Sign in Subscribe
Health care industry

Bionomics and Genetic Technologies Form Strategic Alliance to Commercialize New Genetic Tests for Epilepsy

Strategic Insights

— 2 min read

A new genetic test for severe myoclonic epilepsy in infants (SMEI) has been developed by Bionomics Limited and Genetic Technologies Limited, enabling earlier diagnosis and more precise treatment for this serious form of epilepsy. The test will be launched in partnership with the GENDIA network of international genetic testing laboratories, which will bring the test to over 70 countries around the world, including key markets in the USA and Europe.

The strategic alliance between Bionomics and Genetic Technologies will allow for the commercialization of new genetic tests for epilepsy, with the first test being the SMEI diagnostic tool. This test will assist clinicians in making an earlier diagnosis of SMEI and selecting appropriate treatment strategies for patients. Additional tests in relation to other causes of epilepsy will be added to the program in due course.

Key Takeaways:

  • The strategic alliance between Bionomics and Genetic Technologies will enable the commercialization of new genetic tests for epilepsy.
  • The first test to be launched under this program will identify cases of severe myoclonic epilepsy in infants (SMEI), a serious form of epilepsy in children.
  • The test will be performed by Genetic Technologies and will also be made available to the GENDIA network of international genetic testing laboratories, bringing the test to over 70 countries around the world.
  • Bionomics and its academic collaborators will support Genetic Technologies in the development and marketing of these tests.
  • The test will assist clinicians in making an earlier diagnosis of SMEI and selecting appropriate treatment strategies for patients.
  • Additional tests in relation to other causes of epilepsy will be added to the program in due course.
  • The precise terms of the financial arrangements between Genetic Technologies and Bionomics are covered by confidentiality, but both parties will benefit from the revenues generated from this new alliance.
  • Genetic Technologies will pay Bionomics a signing fee, royalties, and future milestone payments in relation to revenues received from this epilepsy testing, worldwide.
  • Bionomics will also pay Genetic Technologies for a license to the Genetic Technologies non-coding patents.

Statistics:

  • Over 70 countries around the world will have access to the SMEI diagnostic test through the GENDIA network of international genetic testing laboratories.
  • The test will be available in key markets in the USA and Europe.
  • Bionomics has discovered over 600 genes and holds patent applications at various stages of prosecution incorporating utility in specific therapeutic and diagnostic applications.
  • Bionomics is leveraging its expertise and intellectual property to generate both near-term and longer-term revenues.
  • The Company is focusing on central nervous system disorders (particularly epilepsy) and cancer, developing diagnostics for the early detection of these conditions and therapeutics to treat them.

Sources:

  • Bionomics Limited (ASX: BNO, US OTC: BMICY)
  • Genetic Technologies Limited (ASX: GTG, NASDAQ: GNTLY)
  • Asia Pulse 08-11 1350
  • Bionomics Limited website: www.bionomics.com.au
  • GENDIA network of international genetic testing laboratories

Read more